Moberg Pharma AB (MOB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Moberg Pharma AB (MOB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8015
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged nails, Fast relief of pain and itch, Waterproof liquid bandage, minor skin irritations, diaper rash, skin irritation and rash and dry feet and cracked heels in one step. The company works in collaboration to develop Oral mucositis for the treatment of pain in the oral cavity. It offers licencing in and licencing out services. The company markets its products in Europe, South America, Africa, the Middle East and others. Moberg Pharma is headquartered in Stockholm, Sweden.

Moberg Pharma AB (MOB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Moberg Pharma Acquires DermoPlast from Prestige 13
Moberg Pharma Acquires PediaCare Brands from Strides Pharma for USD5.6 Million 15
Moberg Pharma Acquires Three US OTC Brands from Prestige Brands for USD40 Million 16
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 18
Moberg Pharma Acquires Bupivacaine From Oracain 19
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 20
Partnerships 21
Moberg Pharma Enters into Agreement with Colep 21
Moberg Extends Distribution Agreement with Menarini for Emtrix 22
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 23
Moberg Pharma Extends Distribution Agreement With Menarini 24
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 25
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 26
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 27
Moberg Derma Enters Into Co-Marketing Agreement With Ana Darou For Emtrix 28
Licensing Agreements 29
Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 29
Cadila Pharma Enters into Licensing Agreement with Moberg Pharma 30
Equity Offering 31
Moberg Pharma to Raise USD16 Million in Private Placement of Shares 31
Moberg Pharma Raises USD8.6 Million in Private Placement of Shares 32
Moberg Pharma Completes Rights Offering Of Shares For US$5 Million 34
Debt Offering 35
Moberg Pharma Raises USD32.8 million in Public Offering of Bonds 35
Asset Transactions 36
Randob Labs Acquires Balmex from Moberg Pharma for USD4.2 Million 36
Strides Shasun Acquires Jointflex, Fergon and Vanquish Brands from Moberg Pharma for USD10 Million 37
Acquisition 38
Altaris Capital Sells Minority Stake in Moberg Pharma 38
Moberg Derma Completes Acquisition Of Alterna From Altaris Capital Partners For US$25 Million 39
Moberg Pharma AB – Key Competitors 41
Moberg Pharma AB – Key Employees 42
Moberg Pharma AB – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Financial Announcements 44
Aug 07, 2018: Moberg Pharma interim report January – June 2018 44
May 08, 2018: Moberg Pharma Interim report January – March 2018 46
Feb 13, 2018: Moberg Pharma Year-end Report 2017 48
Nov 13, 2017: Moberg Pharma interim report January – September 2017 50
Aug 08, 2017: Moberg Pharma: interim report January- June 2017 51
May 09, 2017: Moberg Pharma interim report January – March 2017 53
Feb 14, 2017: Moberg Pharma Year-end report 2016 54
Corporate Communications 56
Aug 13, 2018: Moberg Pharma appoints new chief medical officer 56
Apr 19, 2018: Moberg Pharma Announces Resignation Of Kjell Rensfeldt As VP Research and Development 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Moberg Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Moberg Pharma Acquires DermoPlast from Prestige 13
Moberg Pharma Acquires PediaCare Brands from Strides Pharma for USD5.6 Million 15
Moberg Pharma Acquires Three US OTC Brands from Prestige Brands for USD40 Million 16
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 18
Moberg Pharma Acquires Bupivacaine From Oracain 19
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 20
Moberg Pharma Enters into Agreement with Colep 21
Moberg Extends Distribution Agreement with Menarini for Emtrix 22
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 23
Moberg Pharma Extends Distribution Agreement With Menarini 24
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 25
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 26
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 27
Moberg Derma Enters Into Co-Marketing Agreement With Ana Darou For Emtrix 28
Cipher Pharma Enters into Licensing Agreement with Moberg Pharma 29
Cadila Pharma Enters into Licensing Agreement with Moberg Pharma 30
Moberg Pharma to Raise USD16 Million in Private Placement of Shares 31
Moberg Pharma Raises USD8.6 Million in Private Placement of Shares 32
Moberg Pharma Completes Rights Offering Of Shares For US$5 Million 34
Moberg Pharma Raises USD32.8 million in Public Offering of Bonds 35
Randob Labs Acquires Balmex from Moberg Pharma for USD4.2 Million 36
Strides Shasun Acquires Jointflex, Fergon and Vanquish Brands from Moberg Pharma for USD10 Million 37
Altaris Capital Sells Minority Stake in Moberg Pharma 38
Moberg Derma Completes Acquisition Of Alterna From Altaris Capital Partners For US$25 Million 39
Moberg Pharma AB, Key Competitors 41
Moberg Pharma AB, Key Employees 42
Moberg Pharma AB, Subsidiaries 43

List of Figures
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Moberg Pharma AB (MOB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Banner Corp:企業の戦略・SWOT・財務情報
    Banner Corp - Strategy, SWOT and Corporate Finance Report Summary Banner Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Oncternal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oncternal Therapeutics Inc (Oncternal) is a clinical-stage oncology company that develops therapies for rare and common cancers. The company’s pipeline compounds include cirmtuzumab and TK216. Its compounds are primarily focused on exciting targets which are uniquely expressed within cancer …
  • Atrium Innovations Inc-製薬・医療分野:企業M&A・提携分析
    Summary Atrium Innovations Inc (Atrium) is a provider of science-based natural health products. The company develops, manufactures and markets nutritional and dietary supplements. Its major products include minerals, vitamins and specialized products such as enzymes and probiotics. Atrium markets it …
  • Galadari Hotels (Lanka) PLC :企業の戦略・SWOT・財務情報
    Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report Summary Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Wilmar International Ltd (F34):企業の財務・戦略的SWOT分析
    Wilmar International Ltd (F34) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Globus Medical Inc (GMED):企業の財務・戦略的SWOT分析
    Globus Medical Inc (GMED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Selcia Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Selcia Ltd (Selcia), formerly SCYNEXIS Europe Ltd is a contract research company that offers drug discovery services. The company operates through its divisions including selcia discovery - a drug discovery operation, incorporating proprietary fragment screening; and Selcia Radiolabeling - t …
  • HCL Technologies Ltd (HCLTECH):企業の財務・戦略的SWOT分析
    HCL Technologies Ltd (HCLTECH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Corvidia Therapeutics:製薬・医療:M&Aディール及び事業提携情報
    Summary Corvidia Therapeutics is a developer of cardiovascular therapies. The company develops cardiovascular therapies leveraging functional genomics. Its pipeline programs are targeted at identifying patients with unique sensitivity to specific biologic pathways, which allows the development of th …
  • Harte Hanks Inc (HHS):企業の財務・戦略的SWOT分析
    Harte Hanks Inc (HHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Grand Haven Board of Light and Power:企業の戦略的SWOT分析
    Grand Haven Board of Light and Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Covea Insurance plc:企業の戦略・SWOT・財務情報
    Covea Insurance plc - Strategy, SWOT and Corporate Finance Report Summary Covea Insurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wilmar International Limited:企業の戦略・SWOT・財務分析
    Wilmar International Limited - Strategy, SWOT and Corporate Finance Report Summary Wilmar International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Japan Pulp and Paper Company Limited:企業の戦略・SWOT・財務情報
    Japan Pulp and Paper Company Limited - Strategy, SWOT and Corporate Finance Report Summary Japan Pulp and Paper Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • AVBOB Mutual Assurance Society:企業の戦略・SWOT・財務分析
    AVBOB Mutual Assurance Society - Strategy, SWOT and Corporate Finance Report Summary AVBOB Mutual Assurance Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Pulmatrix Inc (PULM):製薬・医療:M&Aディール及び事業提携情報
    Summary Pulmatrix Inc (Pulmatrix), formerly Ruthigen Inc is a clinical stage biopharmaceutical company that develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline product using its proprietary inhaled smal …
  • NEC Networks & System Integration Corp (1973):企業の財務・戦略的SWOT分析
    NEC Networks & System Integration Corp (1973) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Spinal Elements Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spinal Elements Inc (Spinal Elements), formerly Quantum Orthopedics Inc, a subsidiary of Spinal Elements, is a medical device manufacturing company that manufactures spinal implants and instruments. The company provides products such as cervical implant systems, anterior cervical plate syste …
  • Arvind Ltd:企業の戦略・SWOT・財務情報
    Arvind Ltd - Strategy, SWOT and Corporate Finance Report Summary Arvind Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • BioHorizons Inc-医療機器分野:企業M&A・提携分析
    Summary BioHorizons Inc (BioHorizons), a subsidiary of Henry Schein Inc is a medical device company that manufactures and develops dental products. The company’s products include dental implants, short implants, guided surgery kits, and others. It provides overdentures, gum grafting and bone graftin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆